Rajput A, Poudel S, Tsunemoto H, Meehan M, Szubin R, Olson CA, Seif Y, Lamsa A, Dillon N, Vrbanac A. Identifying the effect of vancomycin on health care–associated methicillin-resistant Staphylococcus aureus strains using bacteriological and physiological media. GigaScience. 2021;10(1):giaa156.
PubMed PubMed Central Article CAS Google Scholar
Panwala T, Gandhi P, Jethwa D: Inducible Clindamycin resistance and MRSA amongst Staphylococcus aureus isolates: A phenotypic detection.
Thabit AK, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of telavancin against methicillin-susceptible and-resistant Staphylococcus aureus with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2016;60(1):222–8.
CAS PubMed Article Google Scholar
Cascioferro S, Carbone D, Parrino B, Pecoraro C, Giovannetti E, Cirrincione G, Diana P. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections. ChemMedChem. 2021;16(1):65–80.
CAS PubMed Article Google Scholar
Appelbaum PJCM. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12:16–23.
CAS PubMed Article Google Scholar
Selvabai, AP, Sattar, SBA, Jayaraman, P, SHANMUGAM PJJoC, Research D. Detection and Characterisation of Heteroresistant Vancomycin Intermediate Staphylococcus aureus (hVISA) using Phenotypic and Genotypic Methods. J Clin Diagn Res. 2019. https://doi.org/10.7860/JCDR/2019/41127.12868.
Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari EJAR, Control I. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus. Isolates Antimicrob Resist Infect Control. 2021;10(1):1–13.
Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger Quinn PC, JPJTPidj,. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatric Infect Dis J. 2002;21(6):530–4.
Blair J, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJJNrm. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
CAS PubMed Article Google Scholar
Chambers HJPm. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. 2001;109(2 Suppl):43–50.
GM Eliopoulos VG Meka 2004 Gold HSJCID: Antimicrobial resistance to linezolid 39 7 1010 1015
Lewis JS, Jorgensen JHJCID. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40(2):280–5.
Al Jalali V, Zeitlinger M. Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet. 2018;57(7):797–816.
CAS PubMed PubMed Central Article Google Scholar
Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis. 2015;61(4):627–32.
CAS PubMed Article Google Scholar
Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis. 2017;49(7):483–92.
Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides. Drugs. 2010;70(7):859–86.
CAS PubMed Article Google Scholar
Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(3):S214–9.
CAS PubMed Article Google Scholar
Song Y, Lunde CS, Benton BM, Wilkinson BJ. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob Agents Chemother. 2012;56(6):3157–64.
CAS PubMed PubMed Central Article Google Scholar
Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR, Moeck G. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369–71.
CAS PubMed PubMed Central Article Google Scholar
Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015;61(8):1315–21.
CAS PubMed Article Google Scholar
Chen K-H, Huang Y-T, Liao C-H, Sheng W-H, Hsueh P-R. In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother. 2015;59(10):6262–5.
CAS PubMed PubMed Central Article Google Scholar
Mikamo H, Takesue Y, Iwamoto Y, Tanigawa T, Kato M, Tanimura Y, Kohno S. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan–results of a randomised, multicentre phase 3 study. J Infect Chemother. 2018;24(6):434–42.
CAS PubMed Article Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009 Sep;7(9):889–96.
Newcastle O: Newcastle-Ottawa: Scale customized for cross-sectional studies In. In.; 2018.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
CAS PubMed Article Google Scholar
Abdel-Wahab FB, El Menofy N, El-Batal A, Mosalam F, Abdulall AK. Enhanced Antimicrobial Activity of the combination of Silver Nanoparticles and Different β Lactam antibiotics against Methicillin Resistant Staphylococcus aureus isolates. Azhar Int J Phar Med Sci. 2021;1(1):24–33.
Bradley JS. Which antibiotic for resistant gram-positives, and why? J Infect. 2014;68:S63–75.
Hadadi M, Heidari H, Ebrahim-Saraie HS, Motamedifar M. Molecular characterization of vancomycin, mupirocin and antiseptic resistant Staphylococcus aureus strains. Mediter J Hematol Infect Dis. 2018;10(1):e2018053.
Lee C-R, Cho IH, Jeong BC, Lee SH. Strategies to minimize antibiotic resistance. Int J Environ Res Public Health. 2013;10(9):4274–305.
CAS PubMed PubMed Central Article Google Scholar
Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari E. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates. Antimicrob Resist Infect Control. 2021;10(1):1–13.
!!! INVALID CITATION !!! (9, 24–26).
Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from US medical centers. Antimicrob Agents Chemother. 2018;62(3):e20397.
Esposito S, Purrello Sm, Bonnet E, Novelli A, Tripodi F, Pascale R, Unal S, Milkovich G. Central venous catheter-related biofilm infections: An up-to-date focus on meticillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2013;1(2):71–8.
CAS PubMed Article Google Scholar
Di Pilato V, Ceccherini F, Sennati S, D’Agostino F, Arena F, D’Atanasio N, Di Giorgio FP, Tongiani S, Pallecchi L, Rossolini GM. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp biofilms over prolonged exposure times. Diagn Microbiol Infect Dis. 2020;96(2):114901.
PubMed Article CAS Google Scholar
Guest JF, Esteban J, Manganelli AG, Novelli A, Rizzardini G, Serra M. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis. PLoS ONE. 2017;12(11):e0187792.
PubMed PubMed Central Article CAS Google Scholar
Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13). J Antimicrob Chemother. 2015;70(2):498–504.
CAS PubMed Article Google Scholar
Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. InOpen forum infectious diseases. 2017 Jan 1;4;1. Oxford University Press.
Hasannejad-Bibalan M, Mojtahedi A, Biglari H, Halaji M, Sedigh Ebrahim-Saraie H. Antibacterial activity of tedizolid, a novel oxazolidinone against methicillin-resistant Staphylococcus aureus: a systematic review and meta-analysis. Microb Drug Resist. 2019;25(9):1330–7.
CAS PubMed Article Google Scholar
Biedenbach D, Bouchillon S, Johnson B, Alder J, Sahm D. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China. Eur J Clin Microbiol Infect Dis. 2016;35(12):1933–9.
CAS PubMed Article Google Scholar
Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, Picazo JJ. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010;54(5):2212–5.
CAS PubMed PubMed Central Article Google Scholar
Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2016;71(1):152–5.
CAS PubMed Article Google Scholar
Moenster RP, Linneman TW, Call WB, Kay CL, McEvoy TA, Sanders JL. The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults. J Clin Pharm Ther. 2013;38(2):89–96.
CAS PubMed Article Google Scholar
Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.01453-17.
留言 (0)